度普利尤单抗对IGA未达清除或几乎清除的AD患者仍有显著临床获益:两项III期试验汇总分析
LIBERTY AD SOLO 1和2两项16周随机双盲试验的事后分析显示,在16周时IGA>1的成人中重度特应性皮炎患者中,度普利尤单抗300mg每2周组较安慰剂组在EASI、瘙痒NRS、受累BSA、POEM和DLQI等指标上均显著改善。结论提示IGA≤1终点显著低估了度普利尤单抗的临床相关疗效。
要点
- 度普利尤单抗治疗16周时IGA>1的患者仍有EASI、瘙痒、BSA、POEM和DLQI的显著改善
- IGA≤1作为唯一终点可能低估度普利尤单抗的临床获益
- 评估AD疗效时应结合多种 validated 工具而非仅依赖IGA
核心结论
- 在16周时IGA>1的患者中,度普利尤单抗相比安慰剂在多个验证性指标上产生统计学显著获益,IGA≤1终点显著低估其临床相关疗效。
研究设计与样本
- LIBERTY AD SOLO 1和2为两项16周随机双盲试验,纳入局部治疗控制不佳的中重度AD成人患者(IGA≥3)。
- 事后分析比较度普利尤单抗300mg每2周组与安慰剂组中16周时IGA>1患者的结局。
关键数值与推荐
- IGA>1定义为研究者总体评估评分>1(未达清除或几乎清除)。
- POEM和DLQI的临床相关改善阈值分别为≥4分。
临床怎么用
- 对度普利尤单抗治疗16周后IGA未达≤1的AD患者,应结合EASI、瘙痒NRS、BSA、POEM和DLQI综合评估疗效,避免仅凭IGA判定无效。
局限性
- 为事后分析,非预设主要分析。
- 仅纳入两项16周试验的成人中重度AD患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the U.S.A., an Investigator's Global Assessment (IGA) score of ≤ 1 (clear or almost clear skin) has been the standard measure in regulatory outcomes for registration clinical trials in atopic dermatitis (AD), including those supporting the recent approval of dupilumab. OBJECTIVES: To evaluate the treatment effect of dupilumab in patients with IGA > 1 at the end of treatment, using other validated outcome measures for AD signs, symptoms and quality of life. METHODS: LIBERTY AD SOLO 1 and 2 were two 16-week, randomized, double-blind trials enrolling adult patients with moderate-to-severe AD (IGA ≥ 3) inadequately controlled with topical treatment. We performed a post hoc analysis in patients receiving dupilumab 300 mg every 2 weeks (q2w) or placebo. Outcome measures in patients with IGA > 1 included Eczema Area and Severity Index (EASI), pruritus numerical rating scale (NRS), affected body surface area (BSA), Patient-Oriented Eczema Measure (POEM) and Dermatology Life Quality Index (DLQI). The trials were registered at ClinicalTrials.gov: NCT02277743 and NCT02277769. RESULTS: At week 16, 278 of 449 dupilumab q2w-treated patients (median age 36·0 years) and 396 of 443 placebo-treated patients had IGA > 1. Among patients with IGA > 1 at week 16, dupilumab significantly improved several outcome measures compared with placebo: EASI (-48·9% vs. -11·3%, P < 0·001), pruritus NRS (-35·2% vs. -9·1%, P < 0·001), affected BSA (-23·1% vs. -4·5%, P < 0·001), POEM score ≥ 4-point improvement (57·4% vs. 21·0%, P < 0·001) and DLQI score ≥ 4-point improvement (59·3% vs. 24·4%, P < 0·001). CONCLUSIONS: In patients with IGA > 1 at week 16, dupilumab induced statistically significant benefits in multiple validated outcome measures compared with placebo. The IGA ≤ 1 end point significantly underestimates clinically relevant dupilumab treatment effects.
引用
- Silverberg JI, Simpson EL, Ardeleanu M, et al. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. Br J Dermatol. 2019. PMID: 30791102. doi:10.1111/bjd.17791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。